Key result
Empagliflozin added to ramipril reduced GFR by 8 mL/min/1.73 m² compared with placebo plus ramipril and additively lowered clinic blood pressure in patients with type 1 diabetes.
Why the study?
Does adding empagliflozin to ramipril reduce glomerular filtration rate and improve cardiorenal hemodynamic profiles compared with placebo plus ramipril in patients with uncomplicated type 1 diabetes?
RCT (n=30)
Double-blind
Randomized crossover assignment to sequence A or B after 4-week ramipril run-in
No
Does adding empagliflozin to ramipril reduce glomerular filtration rate and improve cardiorenal hemodynamic profiles compared with placebo plus ramipril in patients with uncomplicated type 1 diabetes?
Answers are grounded in this paper and cite their sources.
In patients with type 1 diabetes on ACE inhibitor therapy, adding empagliflozin induces an expected protective dip in GFR, reduces proximal tubular sodium reabsorption and oxidative stress, and additively lowers blood pressure and total peripheral resistance.
Background: The cardiorenal effects of sodium-glucose cotransporter 2 inhibition (empagliflozin 25 mg QD) combined with angiotensin-converting enzyme inhibition (ramipril 10 mg QD) were assessed in this mechanistic study in patients with type 1 diabetes with potential renal hyperfiltration. Methods: Thirty patients (out of 31 randomized) completed this double-blind, placebo-controlled, crossover trial. Recruitment was stopped early because of an unexpectedly low proportion of patients with hyperfiltration. Measurements were obtained after each of the 6 treatment phases over 19 weeks: (1) baseline without treatment, (2) 4-week run-in with ramipril treatment alone, (3) 4-week combined empagliflozin-ramipril treatment, (4) a 4-week washout, (5) 4-week combined placebo-ramipril treatment, and (6) 1-week follow-up. The primary end point was glomerular filtration rate (GFR) after combination treatment with empagliflozin-ramipril compared with placebo-ramipril. GFR was corrected for ramipril treatment alone before randomization. At the end of study phase, the following outcomes were measured under clamped euglycemia (4 to 6 mmol/L): inulin (GFR) and para-aminohippurate (effective renal plasma flow) clearances, tubular sodium handling, ambulatory blood pressure, arterial stiffness, heart rate variability, noninvasive cardiac output monitoring, plasma and urine biochemistry, markers of the renin-angiotensin-aldosterone system, and oxidative stress. Results: Combination treatment with empagliflozin-ramipril resulted in an 8 mL/min/1.73 m 2 lower GFR compared with placebo-ramipril treatment ( P =0.0061) without significant changes to effective renal plasma flow. GFR decrease was accompanied by a 21.3 mL/min lower absolute proximal fluid reabsorption rate ( P =0.0092), a 3.1 mmol/min lower absolute proximal sodium reabsorption rate ( P =0.0056), and a 194 ng/mmol creatinine lower urinary 8-isoprostane level ( P =0.0084) relative to placebo-ramipril combination treatment. Sodium-glucose cotransporter 2 inhibitor/angiotensin-converting enzyme inhibitor combination treatment resulted in additive blood pressure–lowering effects (clinic systolic blood pressure lower by 4 mm Hg [ P =0.0112]; diastolic blood pressure lower by 3 mm Hg [ P =0.0032]) in conjunction with a 94.5 dynes × sex/cm 5 lower total peripheral resistance ( P =0.0368). There were no significant changes observed to ambulatory blood pressure, arterial stiffness, heart rate variability, or cardiac output with the addition of empagliflozin. Conclusions: Adding sodium-glucose cotransporter 2 inhibitor treatment to angiotensin-converting enzyme inhibitor resulted in an expected GFR dip, suppression of oxidative stress markers, additive declines in blood pressure and total peripheral resistance. These changes are consistent with a protective physiologic profile characterized by the lowering of intraglomerular pressure and related cardiorenal risk when adding a sodium-glucose cotransporter 2 inhibitor to conservative therapy. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02632747.
No takes yet. Share an insight, caveat, or question.
Lytvyn et al. (2022) conducted an RCT in Uncomplicated type 1 diabetes with preserved kidney function (n=30). Empagliflozin added to ramipril vs. Placebo + ramipril 10 mg once daily was evaluated on Glomerular filtration rate (GFR) measured by inulin clearance under clamped euglycemia after 4 weeks of treatment (MD -8 mL/min/1.73 m², p=0.0061). Empagliflozin added to ramipril reduced GFR by 8 mL/min/1.73 m² compared with placebo plus ramipril and additively lowered clinic blood pressure in patients with type 1 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: